# Chelator (bifunctional chelating agent)

Source: https://nuclide.cc/terms/chelator-term/  
Nuclide record `chelator-term` (Term). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)"; commercial use needs a licence.

## TL;DR

A molecular 'cage' that grips a radioactive metal atom tightly so it stays attached to the drug all the way to the tumour, instead of leaking out and going to the wrong part of the body.

## Summary

A chelator (or bifunctional chelating agent, BFC/BFCA) is the part of a metal-based radiopharmaceutical that binds the radiometal ion in a stable coordination complex while a second reactive group lets it be covalently attached to a targeting molecule, such as a peptide, antibody or small molecule. The three-part architecture, radiometal plus chelator plus targeting vector (often via a linker), is the standard design of essentially all radiometal radiopharmaceuticals, from diagnostic 68Ga and 64Cu tracers to therapeutic 177Lu, 90Y and 225Ac agents.

DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) is the dominant macrocyclic chelator in the field, used with 68Ga, 111In, 86Y/90Y, 44Sc/47Sc and 177Lu, among others, because its rigid ring gives very high thermodynamic and kinetic stability once the metal is locked in; the trade-off is that labelling usually needs heating (60-95°C for 30-90 minutes), which limits its use with heat-sensitive biomolecules such as intact antibodies. Acyclic chelators (such as DTPA) and other macrocycles (such as NOTA, which forms a stable gallium-68 complex at room temperature) trade some of that ultimate stability for faster, milder labelling conditions.

A poorly matched chelator-metal pair, or incomplete complexation, shows up as radiochemical impurity: unbound or loosely bound radiometal that redistributes in the body (free gallium-68 to bone, free lutetium-177 to bone and liver) rather than following the targeting vector, degrading image quality and increasing off-target dose. Chelator choice is therefore one of the first decisions in designing any new radiometal agent and is documented in the drug's CMC (chemistry, manufacturing and controls) package.

## Fields

- Kind: Term
- Last checked: 2026-09-22

## Sources

- Chemical Society Reviews: matching chelators to radiometals for radiopharmaceuticals: https://pubs.rsc.org/en/content/articlehtml/2014/cs/c3cs60304k
- PMC: the chemical scaffold of theranostic radiopharmaceuticals: https://pmc.ncbi.nlm.nih.gov/articles/PMC9143622/

## Connected records

- terms: [Radiochemical purity (RCP)](https://nuclide.cc/terms/radiochemical-purity/), [Radiolysis (self-radiolysis of radiopharmaceuticals)](https://nuclide.cc/terms/radiolysis/), [Specific activity and molar activity](https://nuclide.cc/terms/specific-activity/)
- isotopes: [Actinium-225](https://nuclide.cc/isotopes/ac-225/), [Copper-64](https://nuclide.cc/isotopes/cu-64/), [Gallium-68](https://nuclide.cc/isotopes/ga-68/), [Indium-111](https://nuclide.cc/isotopes/in-111/), [Lutetium-177](https://nuclide.cc/isotopes/lu-177/), [Scandium-44](https://nuclide.cc/isotopes/sc-44/), [Yttrium-86](https://nuclide.cc/isotopes/y-86/), [Yttrium-90](https://nuclide.cc/isotopes/y-90/)
- technologies: [PET tracer manufacturing and distribution](https://nuclide.cc/technologies/pet-tracer-manufacturing/), [Radionuclide generators and cold kits](https://nuclide.cc/technologies/radionuclide-generators-kits/), [Site-specific conjugation & linker chemistry](https://nuclide.cc/technologies/site-specific-conjugation/)

---
JSON: https://nuclide.cc/api/v1/entities/chelator-term.json